Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study shows Novartis drug could reduce risk of breast cancer returning
February 17th, 2005
A drug currently used against advanced breast cancer may provide better protection against recurrence or spreading than standard medication for post-menopausal women who have been treated for early forms of the disease, Swiss pharmaceutical giant Novartis AG and independent researchers said January 26, 2005. Clinical data presented at a conference on breast cancer in St. Gallen, Switzerland, shows that letrozole, which currently has U.S. approval for use after women finish a lengthy course of the current drug, tamoxifen, reduces the risk the risk of cancer returning or spreading to other parts of the body. "It's a big improvement in treatment," said...
Source: Women's Health Weekly (2005-02-17)
|
